Serelaxin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Serelaxin" in English language version.

refsWebsite

Global rank English rank

18nih.gov

4^th place

11doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

2web.archive.org

1^st place

2novartis.com

low place

1springer.com

274^th place

309^th place

1aerztezeitung.de

low place

aerztezeitung.de

Einecke D (23 November 2012). "Schwangerschaftshormon gegen Herzschwäche" [Pregnancy hormone against heart failure]. Ärzte-Zeitung (in German).

doi.org

Conrad KP (August 2011). "Maternal vasodilation in pregnancy: the emerging role of relaxin". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 301 (2): R267-75. doi:10.1152/ajpregu.00156.2011. PMC 3154715. PMID 21613576.
Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (January 2012). "The role of nitric oxide on endothelial function". Current Vascular Pharmacology. 10 (1): 4–18. doi:10.2174/157016112798829760. PMID 22112350.
Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ (January 2013). "Relaxin family peptides and their receptors". Physiological Reviews. 93 (1): 405–80. doi:10.1152/physrev.00001.2012. PMID 23303914.
Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (June 2010). "Relaxin: review of biology and potential role in treating heart failure". Current Heart Failure Reports. 7 (2): 75–82. doi:10.1007/s11897-010-0010-z. PMC 2875472. PMID 20424993.
Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. (December 2009). "Relaxin, a pleiotropic vasodilator for the treatment of heart failure". Heart Failure Reviews. 14 (4): 321–9. doi:10.1007/s10741-008-9129-3. PMC 2772950. PMID 19101795.
Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al. (February 2014). "A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure". European Heart Journal. 35 (7): 431–41. doi:10.1093/eurheartj/eht459. PMC 3924183. PMID 24255129.
Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG (July 2009). "Relaxin alters cardiac myofilament function through a PKC-dependent pathway". American Journal of Physiology. Heart and Circulatory Physiology. 297 (1): H29-36. doi:10.1152/ajpheart.00482.2008. PMID 19429819.
Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. (January 2013). "Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial". Lancet. 381 (9860): 29–39. doi:10.1016/S0140-6736(12)61855-8. PMID 23141816. S2CID 42821305.
Du XJ, Hewitson TD, Nguyen MN, Samuel CS (2014). "Therapeutic effects of serelaxin in acute heart failure". Circulation Journal. 78 (3): 542–52. doi:10.1253/circj.cj-14-0014. PMID 24451687.
King A (January 2013). "Heart failure. Promising data for serelaxin". Nature Reviews. Cardiology. 10 (1): 3. doi:10.1038/nrcardio.2012.174. PMID 23165078. S2CID 2399731.
Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, et al. (April 2014). "Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial". European Heart Journal. 35 (16): 1041–50. doi:10.1093/eurheartj/eht497. PMC 3992428. PMID 24316514.

nih.gov

pubmed.ncbi.nlm.nih.gov

Conrad KP (August 2011). "Maternal vasodilation in pregnancy: the emerging role of relaxin". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 301 (2): R267-75. doi:10.1152/ajpregu.00156.2011. PMC 3154715. PMID 21613576.
Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C (January 2012). "The role of nitric oxide on endothelial function". Current Vascular Pharmacology. 10 (1): 4–18. doi:10.2174/157016112798829760. PMID 22112350.
Bathgate RA, Halls ML, van der Westhuizen ET, Callander GE, Kocan M, Summers RJ (January 2013). "Relaxin family peptides and their receptors". Physiological Reviews. 93 (1): 405–80. doi:10.1152/physrev.00001.2012. PMID 23303914.
Miyares MA, Davis KA (October 2013). "Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure". P & T. 38 (10): 606–11. PMC 3875246. PMID 24391379.
Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (June 2010). "Relaxin: review of biology and potential role in treating heart failure". Current Heart Failure Reports. 7 (2): 75–82. doi:10.1007/s11897-010-0010-z. PMC 2875472. PMID 20424993.
Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. (December 2009). "Relaxin, a pleiotropic vasodilator for the treatment of heart failure". Heart Failure Reviews. 14 (4): 321–9. doi:10.1007/s10741-008-9129-3. PMC 2772950. PMID 19101795.
Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al. (February 2014). "A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure". European Heart Journal. 35 (7): 431–41. doi:10.1093/eurheartj/eht459. PMC 3924183. PMID 24255129.
Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG (July 2009). "Relaxin alters cardiac myofilament function through a PKC-dependent pathway". American Journal of Physiology. Heart and Circulatory Physiology. 297 (1): H29-36. doi:10.1152/ajpheart.00482.2008. PMID 19429819.
Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. (January 2013). "Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial". Lancet. 381 (9860): 29–39. doi:10.1016/S0140-6736(12)61855-8. PMID 23141816. S2CID 42821305.
Du XJ, Hewitson TD, Nguyen MN, Samuel CS (2014). "Therapeutic effects of serelaxin in acute heart failure". Circulation Journal. 78 (3): 542–52. doi:10.1253/circj.cj-14-0014. PMID 24451687.
King A (January 2013). "Heart failure. Promising data for serelaxin". Nature Reviews. Cardiology. 10 (1): 3. doi:10.1038/nrcardio.2012.174. PMID 23165078. S2CID 2399731.
Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, et al. (April 2014). "Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial". European Heart Journal. 35 (16): 1041–50. doi:10.1093/eurheartj/eht497. PMC 3992428. PMID 24316514.

ncbi.nlm.nih.gov

Conrad KP (August 2011). "Maternal vasodilation in pregnancy: the emerging role of relaxin". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 301 (2): R267-75. doi:10.1152/ajpregu.00156.2011. PMC 3154715. PMID 21613576.
Miyares MA, Davis KA (October 2013). "Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure". P & T. 38 (10): 606–11. PMC 3875246. PMID 24391379.
Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (June 2010). "Relaxin: review of biology and potential role in treating heart failure". Current Heart Failure Reports. 7 (2): 75–82. doi:10.1007/s11897-010-0010-z. PMC 2875472. PMID 20424993.
Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. (December 2009). "Relaxin, a pleiotropic vasodilator for the treatment of heart failure". Heart Failure Reviews. 14 (4): 321–9. doi:10.1007/s10741-008-9129-3. PMC 2772950. PMID 19101795.
Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al. (February 2014). "A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure". European Heart Journal. 35 (7): 431–41. doi:10.1093/eurheartj/eht459. PMC 3924183. PMID 24255129.
Filippatos G, Teerlink JR, Farmakis D, Cotter G, Davison BA, Felker GM, et al. (April 2014). "Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial". European Heart Journal. 35 (16): 1041–50. doi:10.1093/eurheartj/eht497. PMC 3992428. PMID 24316514.

novartis.com

"FDA grants breakthrough designation to Novartis' serelaxin (RLX030) for acute heart failure". Novartis Global. Archived from the original on 2 March 2014.
"Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure". Global Novartis News Archive. Archived from the original on 10 July 2018.

semanticscholar.org

api.semanticscholar.org

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. (January 2013). "Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial". Lancet. 381 (9860): 29–39. doi:10.1016/S0140-6736(12)61855-8. PMID 23141816. S2CID 42821305.
King A (January 2013). "Heart failure. Promising data for serelaxin". Nature Reviews. Cardiology. 10 (1): 3. doi:10.1038/nrcardio.2012.174. PMID 23165078. S2CID 2399731.

springer.com

adisinsight.springer.com

"Serelaxin - Novartis". Adis Insight. Springer Nature Switzerland AG.

web.archive.org

"FDA grants breakthrough designation to Novartis' serelaxin (RLX030) for acute heart failure". Novartis Global. Archived from the original on 2 March 2014.
"Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure". Global Novartis News Archive. Archived from the original on 10 July 2018.